This article is more than 5 years old. Information may no longer be current.

New genetic test aims to guide vitamin therapy choices in AMD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ArcticDx Inc. announced that its Vita Risk pharmacogenetic analysis will be available as part of the new Macula Risk PGx test, according to a company press release.

The Macula Risk PGx test is intended for patients diagnosed with early or intermediate age-related macular degeneration, the company said. The test predicts a patient’s risk of progression to advanced AMD within 2, 5 and 10 years using an analysis of AMD genes, clinical status and significant nongenetic risk factors.

The Vita Risk portion of the test uses data from 995 patients in the Age-Related Eye Disease Study to provide a recommendation of zinc alone, antioxidants plus zinc or antioxidants alone, the press release said.

According to a recently published study, the presence of complement factor H and age-related maculopathy sensitivity 2 risk alleles can predict a patient’s response to these vitamins.

“This data demonstrates that the composition of supplements recommended to AMD patients should be guided by an individual’s genetic risk profile,” study author Carl S. Awh, MD, said in the press release.

Disclosure: Awh is an equity owner of ArcticDx.